• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Octapharma - Articles and news items

nuwiq

FDA approves Octapharma’s Nuwiq for haemophilia A

Industry news / 16 September 2015 / Victoria White

Nuwiq is the first B-domain deleted recombinant Factor VIII derived from a human cell-line designed for the treatment of patients with haemophilia A…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +